The story of (cerivastatin) is a cautionary tale of a medical breakthrough that turned into a pharmaceutical crisis, ultimately leading to one of the most significant drug recalls in history. The Rise of a "Blockbuster"

While all statins carry a minor risk of this condition, Baycol’s risk was found to be significantly higher. The danger escalated dramatically when the drug was taken in combination with , another cholesterol medication; in these cases, the risk of muscle destruction was up to 10 times higher than with other statins. The Fall and Recall

As Baycol’s popularity grew, so did reports of a rare but devastating side effect: . This condition causes muscle tissue to break down and leak into the bloodstream, which can lead to severe muscle pain, kidney failure, and death.

Baycol was fast-acting and highly effective at lower doses than its competitors, quickly becoming Bayer's third best-selling drug. By 2001, it was used by nearly 700,000 people in the United States alone. The Hidden Danger

In the late 1990s, the pharmaceutical world was in a race to solve a growing global health crisis: high cholesterol. Bayer, the German pharmaceutical giant, introduced Baycol in 1997 as a powerful addition to the "statin" family—a class of drugs designed to block cholesterol production in the liver.

By 2001, the evidence became impossible to ignore. Internal documents later suggested that Bayer may have been aware of these risks as early as the drug's US approval in 1997. On , Bayer voluntarily withdrew Baycol from the global market following reports linking it to 31 deaths in the U.S. and dozens more worldwide. Study: Baycol risks greaterthan believed - NBC News